---
schema_version: "secwatch.filing_event.v1"
accession: "0000920148-25-000111"
form_type: "8-K"
ticker: "LH"
cik: "0000920148"
company_name: "LABCORP HOLDINGS INC."
filed_at: "2025-11-24T23:59:59+00:00"
generated_at: "2026-05-16T17:30:24.057614+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Labcorp appoints Novartis U.S. President Victor Bulto to Board of Directors

## Summary
- Victor Bulto appointed to Labcorp's Board effective December 1, 2025; he is President of Novartis U.S. and member of Novartis Executive Committee.
- Bulto brings 25 years of healthcare experience and oversees Novartis' $20B+ U.S. business across oncology, immunology, neuroscience, and cardiovascular-renal-metabolic areas.
- CEO Adam Schechter stated Bulto's expertise in therapeutic areas and transformation will support Labcorp's innovation and long-term growth strategy.
- Bulto will receive compensation consistent with Labcorp's director compensation program as described in the April 4, 2025 proxy statement.

## SEC filing metadata
- accession: 0000920148-25-000111
- form_type: 8-K
- ticker: LH
- cik: 0000920148
- company_name: LABCORP HOLDINGS INC.
- filed_at: 2025-11-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/920148/000092014825000111/0000920148-25-000111-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/920148/000092014825000111/lh-20251120.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000920148-25-000111
- JSON: https://secwatch.observer/filing/0000920148-25-000111.json
- Plain text: https://secwatch.observer/filing/0000920148-25-000111.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.